Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects.

Trial Profile

Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2018

At a glance

  • Drugs Abatacept (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2050 RDI link 34746 has been retained as the company has decided to explore combination therapy of insulin B-chain vaccine and abatacept.
    • 31 Aug 2018 Biomarkers information updated
    • 30 Aug 2018 Results examining post-onset diabetes progression in local patients from the Children's Hospital of Wisconsin and participants in the TN-09 trial published in the Diabetologia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top